The FDA has approved AstraZeneca and Merck & Co’s Lynparza (olaparib) in metastatic castration-resistant prostate cancer, just days after the regulator gave the nod for Clovis’ PARP-cla
The FDA has granted AstraZeneca/MSD’s PARP-targeting drug Lynparza a fast review in prostate cancer, following hot on the heels of rival Clovis and its Rubraca and targeting a wider patient
The FDA has granted a fast review for Clovis Oncology’s Rubraca PARP drug in certain patients with prostate cancer, the first drug in this class to target the indication.
NICE has reversed its decision on Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) and will allow the drug to be used on the Cancer Drugs Fund (CDF), after the manufacturer offered a lower p